Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau

Recurrent ovarian cancer (OvCa) is thought to result in part from the inability to eliminate rare quiescent cancer stem cells (CSCs) that survive cytotoxic chemotherapy and drive tumor resurgence. The Sialyl-Thomsen-nouveau antigen (STn) is a carbohydrate moiety present on protein markers of CSCs in...

Descripción completa

Detalles Bibliográficos
Autores principales: Starbuck, Kristen, Al-Alem, Linah, Eavarone, David A., Hernandez, Silvia Fatima, Bellio, Chiara, Prendergast, Jillian M., Stein, Jenna, Dransfield, Daniel T., Zarrella, Bianca, Growdon, Whitfield B., Behrens, Jeff, Foster, Rosemary, Rueda, Bo R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955411/
https://www.ncbi.nlm.nih.gov/pubmed/29796189
http://dx.doi.org/10.18632/oncotarget.25289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955411/
https://www.ncbi.nlm.nih.gov/pubmed/29796189
http://dx.doi.org/10.18632/oncotarget.25289

Ejemplares similares